Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. (now transitioning to Harrow Health, Inc.) on December 13, 2018. The report details a corporate name change approved by the Board of Directors and the disclosure of a corporate presentation used at investor conferences.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and disclosure rather than financial performance data.
Material Changes
- Name Change: The Board of Directors initiated a process to change the company name from "Imprimis Pharmaceuticals, Inc." to "Harrow Health, Inc." under Delaware General Corporations Law.
- Shareholder Action: No shareholder approval or action is required for the name change. Existing stock certificates remain valid, though shareholders may request updated certificates with a new CUSIP number after the change is finalized.
- Timeline: The name change is anticipated to be completed within thirty days of the report date.
Guidance, Outlook, and Risks
The filing includes a Regulation FD disclosure referencing a corporate presentation (Exhibit 99.1) used by management at investor meetings. The text explicitly states that the information in the presentation is not deemed "filed" for purposes of the Securities Exchange Act of 1934 and is not incorporated by reference unless specifically cited in another filing. No specific financial guidance, risks, or contingencies are detailed within the body of this 8-K.
Investor Verification Checklist
- Confirm the official completion date of the name change to "Harrow Health, Inc."
- Verify the new CUSIP number once the name change is finalized.
- Review the attached Exhibit 99.1 (Corporate Presentation) for strategic context, noting it is not a filed document.
- Check subsequent filings for the first financial report under the new corporate name.